The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index; 35 of the 93 sources its claims cite were checked for support.
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Open accessAbstract
Glucagon-like peptide-1 (GLP-1) is an incretin hormone mainly secreted from intestinal L cells in response to nutrient ingestion. GLP-1 has beneficial effects for glucose homeostasis by stimulating insulin secretion from pancreatic beta-cells, delaying gastric emptying, decreasing plasma glucagon, reducing food intake, and stimulating glucose disposal. Therefore, GLP-1-based therapies such as GLP-1 receptor agonists and inhibitors of dipeptidyl peptidase-4, which is a GLP-1 inactivating enzyme, have been developed for treatment of type 2 diabetes. In addition to glucose-lowering effects, emerging data suggests that GLP-1-based therapies also show anti-inflammatory effects in chronic inflammatory diseases including type 1 and 2 diabetes, atherosclerosis, neurodegenerative disorders, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, and psoriasis. This review outlines the anti-inflammatory actions of GLP-1-based therapies on diseases associated with chronic inflammation in vivo and in vitro, and their molecular mechanisms of anti-inflammatory action.
Overview
CoChat Summary
## TL;DR
This review argues that GLP-1-based therapies have anti-inflammatory effects beyond glucose lowering, with evidence across diabetes, vascular disease, brain disorders, liver disease, nephropathy, and other inflammatory conditions. It summarizes in vitro, animal, and some human findings showing reductions in inflammatory cytokines, immune-cell infiltration, and related signaling pathways.
## Key findings
- In diabetes, GLP-1-based therapies reduced inflammatory mediators in islets and adipose tissue: liraglutide (100 nM) inhibited palmitate-induced TNF-α, IL-1β, and IL-6 in mouse islets; sitagliptin (100 mg/day) reduced plasma CRP, IL-6, IL-18, secreted phospholipase-A2, soluble ICAM-1, and E-selectin in type 2 diabetes patients, while the inflammatory score and HOMA index for insulin resistance were also significantly reduced.
- In vascular disease, liraglutide reduced adhesion molecules in endothelial cells and exendin-4 reduced atherosclerosis in mice; for example, exendin-4 (50 μg/kg/day) reduced atherosclerosis development and monocyte adhesion in APOE*3-Leiden.CETP mice, and sitagliptin reduced plaque macrophage infiltration and MMP-9 in ApoE−/− mice.
- In neurodegenerative disease models, liraglutide reduced activated microglia and inflammatory responses in Alzheimer’s disease models, and exendin-4 (10 μg/kg) decreased MPTP-induced microglial activation and TNF-α/IL-1β in Parkinson’s disease models.
- In other conditions, liraglutide improved asthma-related inflammation (including lower E-selectin, TNF-α, IL-4, IL-5, and IL-13) and exenatide improved sperm quality in diet-induced obese mice by suppressing testicular TNF-α, MCP-1, and F4/80.
## Methods
- Narrative review of published in vivo and in vitro studies on GLP-1, GLP-1 receptor agonists, and DPP-4 inhibitors across inflammatory diseases.
- Evidence base includes cell models, rodent and other animal models, and selected human studies (for example, patients with type 2 diabetes and nonalcoholic steatohepatitis).
- Main analysis was qualitative synthesis of anti-inflammatory effects and molecular mechanisms, organized by disease area and signaling pathways.
## Limitations
- The paper states that some reported benefits “need to be validated by clinical studies” for asthma, and that the safety of GLP-1-based therapy should be validated by “sufficient further studies” because rare cases of acute pancreatitis and neoplasms have been reported.
- Evident from the text: this is a review, so many conclusions are based on preclinical or small clinical studies rather than a single controlled synthesis or meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
26 Valid · 0 Not valid · 23 Not checked · 23 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Inflammation can be a mediator of insulin resistance and beta-cell damage by high glucose, fatty acids, or adipokines released from adipose tissues [37–39].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 2. Diabetes
What the sources say
- Partly supportedcites [37] sourceExperimental — accuracy not yet measured
The “Autoimmunity and inflammation” section (page not provided) says high glucose and free fatty acids induce islet inflammation that contributes to beta-cell impairment and apoptosis. The “Adipokines” section says some adipose-derived factors promote inflammation and beta-cell failure. The paper does not establish that inflammation mediates insulin resistance, so that part of the attributed claim is unsupported. (LLM, conf=0.84)
- Partly supportedcites [38] sourceExperimental — accuracy not yet measured
The “Metabolic and Oxidative Stress” passage links glucotoxicity and lipotoxicity to β-cell damage. The “Inflammation” passage describes local islet inflammation in type 2 diabetes and says anti-inflammatory treatment can preserve some β-cell functional mass. Our copy does not establish that inflammation mediates insulin resistance or damage caused by adipose-derived adipokines, and it leaves the origin of islet inflammation unresolved. The indexed passages provide no page numbers. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [39] source
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Therefore, suppression of CXCL10 production by exendin-4 could reduce islet inflammation by decreasing cytotoxic T lymphocyte recruitment into the islets in autoimmune type 1 diabetes [48].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 2. Diabetes
What the sources say
- Supportedcites [48] source
The paper's own Results ("Suppression of IFN-γ-induced CXCR3-binding chemokines by exendin-4 and cyclic AMP in human islets") show exendin-4 suppressing CXCL10 mRNA (~30% with rolipram, modest but significant with exendin-4 alone) and protein (38%), with reduced secretion into the medium, and the Introduction states that "CXCL10 plays an important role in trafficking effector T cells to islets during insulitis in type 1 diabetes" and that "suppression of CXCL10 production in islets could be an important therapeutic approach to reducing insulitis in type 1 diabetes." The citing sentence's hedged inference ("could reduce islet inflammation by decreasing ... T lymphocyte recruitment") reproduces that same reasoning, with "cytotoxic T lymphocyte" standing in for the source's CXCR3-bearing effector/activated T cells and NK cells. The source is in vitro human islets and MIN6 cells, so the type 1 diabetes benefit remains a stated possibility in both documents, not a demonstrated outcome. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17]”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 1. Introduction
What the sources say
- Partly supportedcites [12] sourceExperimental — accuracy not yet measured
The Results section (page unavailable) reports GLP-1 receptor expression in lung, pancreatic β-cells, and endothelial cells; the introductory text also refers broadly to neural cells. The paper does not establish receptor expression in the kidney, heart, hypothalamus, astrocytes, or microglia, nor does it identify neurons specifically. Its discussion of GLP-1 effects on the heart is not evidence of receptor expression there. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [13] source
- Not checked — no full text of the sourcecites [14] source
- Not checked — no full text of the sourcecites [15] source
- Not checked — no full text of the sourcecites [16] source
- Not checked — no full text of the sourcecites [17] source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Thus, GLP-1 therapy may be beneficial for the treatment of chronic inflammatory diseases including nonalcoholic steatohepatitis, atherosclerosis, neurodegenerative disorders, diabetic nephropathy, asthma, and psoriasis [14, 26–32].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [14] source
- Partly supportedcites [26] sourceExperimental — accuracy not yet measured
Vittone et al. (2012) supports only the atherosclerosis element of the list: the Discussion (p. 6) states that sitagliptin 'decreases plaque macrophage content and stabilises arteriosclerotic lesions in Apoe -/- mice, while GLP-1 directly inhibits monocyte migration and macrophage MMP-9 production in vitro', and the same passage notes broadly that 'there is evidence of anti-inflammatory effects of GLP-1 in different tissues'. Our copy makes no claim that GLP-1 therapy is beneficial in nonalcoholic steatohepatitis, diabetic nephropathy or asthma (searched: those terms plus 'chronic inflammatory diseases'); neurodegenerative and psoriatic disease appear only as titles of cited works (refs 25 and 26, References p. 9), not as conditions this paper shows GLP-1 treats. The remaining diseases in the citing list must rest on the other citations in the cluster [14, 26–31]. (LLM, conf=0.78)
- Not checked — no full text of the sourcecites [27] source
- Not checked — no full text of the sourcecites [28] source
- Not checked — no full text of the sourcecites [29] source
- Not checked — no full text of the sourcecites [30] source
- Partly supportedcites [31] sourceExperimental — accuracy not yet measured
The Conclusions/interpretation and Discussion (pages not provided) suggest therapeutic potential for GLP-1 in inflammatory conditions such as psoriasis, based on improvement observed in patients. The Discussion also mentions cardiovascular and neuroprotective effects, but the paper does not support the full list of proposed treatments, particularly nonalcoholic steatohepatitis, diabetic nephropathy, and asthma. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [32] source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“emerging data suggest that GLP-1-based therapies also showed anti-inflammatory effects on the liver, vascular system including aorta and vein endothelial cells, brain, kidney, lung, testis, and skin by reducing the production of inflammatory cytokines and infiltration of immune cells in the tissues [17, 21–25].”
§ Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [17] source
- Partly supportedcites [21] sourceExperimental — accuracy not yet measured
The GLP-1RAs AND INFLAMMATION section reports anti-inflammatory effects in endothelial cells and reduced inflammatory-cytokine release; the IL-6 and chemokines sections report reductions in the liver, brain, and kidney. The monocytes/macrophages section reports reduced macrophage infiltration in adipose tissue, not across the listed organs. The cited passages do not establish anti-inflammatory effects in the aorta, lung, testis, or skin. Page numbers were not available in our copy. (LLM, conf=0.88)
- Could not verifycites [22] sourceExperimental — accuracy not yet measured
Our copy of Blandino-Rosano et al. (2008) is confined to rat pancreatic islet/β-cell culture: the Abstract and the results section 'GLP-1 has a protective role against anti-proliferative effects of cytokines' show GLP-1 reversing IL-1β/IFN-γ/TNF-α-induced ERK1/2 inactivation and restoring β-cell proliferation, and the Discussion frames this as possible use in early-stage DM1. No passage addresses anti-inflammatory actions of GLP-1-based therapies in liver, aorta/vein endothelium, brain, kidney, lung, testis or skin, nor reduced cytokine production or immune-cell infiltration in those tissues (searched: extrapancreatic tissues/endothelial/kidney/anti-inflammatory in vivo; inflammatory cytokine production and immune infiltration). Since our copy neither states nor contradicts the tissue-level claim, it cannot be verified from this source. (LLM, conf=0.70)
- Partly supportedcites [23] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [24] source
- Partly supportedcites [25] sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
47 more claims · 13 with their cited sources checked
Create a free account to see all 72 claims and to verify the 6 references still open.
- It may state two separate claims as one. 20
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1RAs have effects on systemic inflammation such as reduction in high-sensitivity C-reactive protein (hs-CRP) that are not mediated by weight loss or glycemic control [15, 27, 28].”
From evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer’s disease (2025) · cites this paper as [27]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There is increasing evidence that GLP-1RAs act as modulators of atherosclerosis, 76 and their anti-inflammatory and antioxidant properties may contribute to this, as supported by laboratory studies. 77,78”
The cited source says what the claim attributes to it.
In the citing paper
“Experimental and translational data support anti‐inflammatory and antioxidant actions of GLP‐1RAs beyond glycemic control [5].”
The cited source says what the claim attributes to it.
In the citing paper
“These benefits suggest important non‐glycemic effects, including modulation of inflammatory and vascular pathways [5].”
The cited source says what the claim attributes to it.
In the citing paper
“GLP‐1 receptor signalling may inhibit pro‐inflammatory transcriptional pathways, attenuate oxidative stress, improve endothelial function and modulate immune cell activation [5, 10].”
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
“Nonalcoholic steatohepatitis [61, 93, 96]”
Cited work 10.1007/s00125-010-1831-8 · retracted 2011-12-15 · notice 10.1007/s00125-011-2394-z · this paper published 2016
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · cited 3×
“Nonalcoholic steatohepatitis [61, 93, 96]”
BackgroundRetractedRole of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Kanda, H. (2006) · Journal of Clinical Investigation · doi:10.1172/jci26498 · Cited by 2,682
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“GLP-1 has many beneficial effects on the control of blood glucose levels including stimulation of insulin secretion and inhibition of glucagon secretion, expansion of the beta-cell mass by stimulating beta-cell proliferation and differentiation and inhibiting beta-cell apoptosis, delay of gastric emptying, and reducti…”
BackgroundMicroglia and inflammation-mediated neurodegeneration: Multiple triggers with a common mechanism
Block, M. L., & Hong, J.-S. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.06.004 · Cited by 1,557
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P., Hunter, D., Huber, R., Lemieux, J., Slaymaker, S., Vaddi, K., Charo, I., Leibel, R. L., & Jr., A. W. F. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335 · Cited by 1,497
Mechanisms of Pancreatic β-Cell Death in Type 1 and Type 2 Diabetes
Cnop, M., Welsh, N., Jonas, J.-C., Jörns, A., Lenzen, S., & Eizirik, D. L. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s97 · Cited by 1,491
CCR2 modulates inflammatory and metabolic effects of high-fat feeding
Weisberg, S. P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci24335c1 · Cited by 1,425
Normalization of obesity-associated insulin resistance through immunotherapy
Winer, S., Chan, Y., Paltser, G., Truong, D., Tsui, H., Bahrami, J., Dorfman, R., Wang, Y., Zielenski, J., Mastronardi, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2001 · Cited by 1,370
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Immunity, atherosclerosis and cardiovascular disease
Frostegård, J. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-117 · Cited by 1,040 · cited 1×
“Atherosclerosis is a chronic inflammatory condition resulting from the invasion and accumulation ofwhite blood cells (foamcells) in thewalls of arteries and therefore is a syndrome affecting arterial blood vessels [58].”
BackgroundTissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919
Insulin Action, Diabetogenes, and the Cause of Type II Diabetes
Kahn, C. R. (1994) · Diabetes · doi:10.2337/diab.43.8.1066 · Cited by 916
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698 · cited 1×
“Liraglutide (25 nmol/kg/day) treatment significantly reduced the inflammatory response in the cortex as measured by the number of activated microglia and prevented degenerative processes in a 7-month-old APPSWE/PS1ΔE9 mouse model of Alzheimer’s disease [86].”
BackgroundStehouwer, C. D. A., Gall, M.-A., Twisk, J. W. R., Knudsen, E., Emeis, J. J., & Parving, H.-H. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1157 · Cited by 652
Glia and their cytokines in progression of neurodegeneration
Mrak, R. E., & Griffin, W. S. T. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.05.010 · Cited by 592 · cited 1×
“Neurodegenerative central nervous system disorders are associated with chronic neuroinflammation [75–77].”
BackgroundThe Influence of GLP-1 on Glucose-Stimulated Insulin Secretion
Kjems, L. L., Holst, J. J., Vølund, A., & Madsbad, S. (2003) · Diabetes · doi:10.2337/diabetes.52.2.380 · Cited by 582
Arakawa, M., Mita, T., Azuma, K., Ebato, C., Goto, H., Nomiyama, T., Fujitani, Y., Hirose, T., Kawamori, R., & Watada, H. (2010) · Diabetes · doi:10.2337/db09-1694 · Cited by 548 · cited 1×
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17], suggesting that GLP-1 might have additional roles other than glucoselowering effects.”
BackgroundHunter, K., & Hölscher, C. (2012) · BMC Neuroscience · doi:10.1186/1471-2202-13-33 · Cited by 504
Göke, R., Larsen, P. J., Mikkelsen, J. D., & Sheikh, S. P. (1995) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1995.tb00650.x · Cited by 474 · cited 1×
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17], suggesting that GLP-1 might have additional roles other than glucoselowering effects.”
Backgroundβ-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment
Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · Diabetes Care · doi:10.2337/dc14-0396 · Cited by 460
Mechanisms of β-Cell Death in Type 2 Diabetes
Donath, M. Y., Ehses, J. A., Maedler, K., Schumann, D. M., Ellingsgaard, H., Eppler, E., & Reinecke, M. (2005) · Diabetes · doi:10.2337/diabetes.54.suppl_2.s108 · Cited by 444
Nauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
Kodera, R., Shikata, K., Kataoka, H. U., Takatsuka, T., Miyamoto, S., Sasaki, M., Kajitani, N., Nishishita, S., Sarai, K., Hirota, D., et al. (2011) · Diabetologia · doi:10.1007/s00125-010-2028-x · Cited by 394
McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 361 · cited 1×
“In addition, in the 14-month-old APPSWE/PS1ΔE9 mouse, inflammation was also markedly reduced and restorative effects were improved by liraglutide treatment [91].”
BackgroundLong-Acting Glucagon-Like Peptide 1 Receptor Agonists
Garber, A. J. (2011) · Diabetes Care · doi:10.2337/dc11-s231 · Cited by 350
Fujita, H., Morii, T., Fujishima, H., Sato, T., Shimizu, T., Hosoba, M., Tsukiyama, K., Narita, T., Takahashi, T., Drucker, D. J., et al. (2014) · Kidney International · doi:10.1038/ki.2013.427 · Cited by 336 · cited 2×
“GLP-1 receptor deficiency in the diabetic nephropathy-resistant C57BL/6-Akita mouse contributes to the development of diabetic nephropathy, and liraglutide treatment suppressed the progression of nephropathy of the KK/Ta-Akita mouse, which shows high susceptibility to diabetic nephropathy [14], suggesting that GLP-1 a…”
BackgroundInsulin metabolism and the risk of Alzheimer disease: The Rotterdam Study
Schrijvers, E. M. C., Witteman, J. C. M., Sijbrands, E. J. G., Hofman, A., Koudstaal, P. J., & Breteler, M. M. B. (2010) · Neurology · doi:10.1212/wnl.0b013e3181ffe4f6 · Cited by 328
The role of glial cells in Parkinsonʼs disease
Vila, M., Jackson-Lewis, V., Guégan, C., Chu Wu, D., Teismann, P., Choi, D.-K., Tieu, K., & Przedborski, S. (2001) · Current Opinion in Neurology · doi:10.1097/00019052-200108000-00009 · Cited by 326 · cited 1×
“Microglial activation plays a critical role in the pathogenesis of the 1-methyl-4-phenyl1,2,3,6-tetrahydropyidine- (MPTP-) induced Parkinson’s disease model and human Parkinson’s disease [27].”
BackgroundLee, Y.-S., Park, M.-S., Choung, J.-S., Kim, S.-S., Oh, H.-H., Choi, C.-S., Ha, S.-Y., Kang, Y., Kim, Y., & Jun, H.-S. (2012) · Diabetologia · doi:10.1007/s00125-012-2592-3 · Cited by 319
Self-citationAnti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells
Lee, Y.-S., & Jun, H.-S. (2014) · Metabolism · doi:10.1016/j.metabol.2013.09.010 · Cited by 315 · cited 1×
“GLP-1 has many beneficial effects on the control of blood glucose levels including stimulation of insulin secretion and inhibition of glucagon secretion, expansion of the beta-cell mass by stimulating beta-cell proliferation and differentiation and inhibiting beta-cell apoptosis, delay of gastric emptying, and reducti…”
BackgroundSelf-citationAutoimmune Destruction of Pancreatic β Cells
Yoon, J.-W., & Jun, H.-S. (2005) · American Journal of Therapeutics · doi:10.1097/01.mjt.0000178767.67857.63 · Cited by 308 · cited 1×
“Type 1 diabetes is caused by autoimmune-mediated destruction of pancreatic beta-cells [33], and type 2 diabetes is caused by both insulin resistance and relative deficiency of insulin [34–36].”
BackgroundSelf-citationA Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296
Insulin Resistance or Insulin Deficiency: Which Is the Primary Cause of NIDDM?
Taylor, S. I., Accili, D., & Imai, Y. (1994) · Diabetes · doi:10.2337/diab.43.6.735 · Cited by 289
Crajoinas, R. O., Oricchio, F. T., Pessoa, T. D., Pacheco, B. P. M., Lessa, L. M. A., Malnic, G., & Girardi, A. C. C. (2011) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00729.2010 · Cited by 278 · cited 1×
“The GLP-1 receptor is expressed in glomerular capillaries and vascular walls of themouse kidney [14, 101] and in the glomerulus and proximal convoluted tubules of the rat and pig [29, 102].”
BackgroundMatsubara, J., Sugiyama, S., Sugamura, K., Nakamura, T., Fujiwara, Y., Akiyama, E., Kurokawa, H., Nozaki, T., Ohba, K., Konishi, M., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.07.053 · Cited by 273 · cited 1×
“Des-fluorositagliptin (200mg/kg/day) treatment reduced atherosclerotic lesion formation, infiltration of macrophage and T lymphocytes, and the expression of proinflammatory cytokines within plaques in ApoE mice [68].”
BackgroundPussinen, P. J., Tuomisto, K., Jousilahti, P., Havulinna, A. S., Sundvall, J., & Salomaa, V. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.106.138743 · Cited by 265
Shiraki, A., Oyama, J.-I., Komoda, H., Asaka, M., Komatsu, A., Sakuma, M., Kodama, K., Sakamoto, Y., Kotooka, N., Hirase, T., et al. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.12.039 · Cited by 263
Kim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263 · cited 12×
“Sitagliptin (10mg/kg/day) treatment decreased the expression of proinflammatory cytokine genes IL-1𝛽 and TNF-𝛼 in kidney of diabetic ZDF rat [25].”
BackgroundInfluentialDiabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients
Saraheimo, M., Teppo, A.-M., Forsblom, C., Fagerudd, J., & Groop, P.-H. (2003) · Diabetologia · doi:10.1007/s00125-003-1194-5 · Cited by 255 · cited 1×
“Diabetic nephropathy is associated with a state of lowgrade inflammation in the microvasculature of the kidney’s glomeruli [99, 100].”
BackgroundIFN- gamma and tumor necrosis factor- alpha . Cytotoxicity to murine islets of Langerhans.
Campbell, I. L., Iscaro, A., & Harrison, L. C. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.7.2325 · Cited by 233
Bakos, H. W., Henshaw, R. C., Mitchell, M., & Lane, M. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.11.044 · Cited by 230 · cited 1×
“Obesity can reduce the quality and count of men’s sperm [111, 112].”
BackgroundHamilton, A., & Hölscher, C. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832fbf14 · Cited by 227
Hamilton, A., Patterson, S., Porter, D., Gault, V. A., & Holscher, C. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22565 · Cited by 210 · cited 1×
“Models of Alzheimer’s disease include intracerebroventricular injection of STZ [88], intracerebral injection of LPS [88], and the APPSWE/PS1ΔE9 mouse [84].”
MethodGlucagon-like peptide-1 inhibits LPS-induced IL-1β production in cultured rat astrocytes
Iwai, T., Ito, S., Tanimitsu, K., Udagawa, S., & Oka, J.-I. (2006) · Neuroscience Research · doi:10.1016/j.neures.2006.04.008 · Cited by 207
Diabetes and beta cell function: from mechanisms to evaluation and clinical implications
Cernea, S., & Dobreanu, M. (2013) · Biochemia Medica · doi:10.11613/bm.2013.033 · Cited by 203 · cited 1×
“Inflammation can be a mediator of insulin resistance and beta-cell damage by high glucose, fatty acids, or adipokines released from adipose tissues [37–39].”
BackgroundBalestrieri, M. L., Rizzo, M. R., Barbieri, M., Paolisso, P., D’Onofrio, N., Giovane, A., Siniscalchi, M., Minicucci, F., Sardu, C., D’Andrea, D., et al. (2015) · Diabetes · doi:10.2337/db14-1149 · Cited by 196 · cited 1×
“In diabetic patients treated with GLP-1-based therapy, the protein level of SIRT6 in asymptomatic plaques was significantly increased and TNF-α and MMP-9 levels in lesions were significantly reduced compared with diabetic patients without treatment [8].”
Hogan, A. E., Tobin, A. M., Ahern, T., Corrigan, M. A., Gaoatswe, G., Jackson, R., O’Reilly, V., Lynch, L., Doherty, D. G., Moynagh, P. N., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2232-3 · Cited by 191 · cited 1×
“In type 2 diabetes patients, GLP-1 and liraglutide also improve clinical symptoms of psoriasis, a skin inflammatory disease, by downregulation of invariant natural killer T cells [31, 113, 114].”
BackgroundLiu, H., Dear, A. E., Knudsen, L. B., & Simpson, R. W. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0468 · Cited by 187
Krasner, N. M., Ido, Y., Ruderman, N. B., & Cacicedo, J. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097554 · Cited by 186 · cited 1×
“which are cAMP/Ca signaling pathways [60].”
Eguchi, Y., Kitajima, Y., Hyogo, H., Takahashi, H., Kojima, M., Ono, M., Araki, N., Tanaka, K., Yamaguchi, M., Matsuda, Y., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12351 · Cited by 182 · cited 1×
“9mg/person/day) therapy for 96 weeks resulted in improvement of histological indicators of inflammation in seven subjects out of ten subjects [97].”
Plaschke, K., & Hoyer, S. (1993) · International Journal of Developmental Neuroscience · doi:10.1016/0736-5748(93)90021-5 · Cited by 178 · cited 1×
“Models of Alzheimer’s disease include intracerebroventricular injection of STZ [88], intracerebral injection of LPS [88], and the APPSWE/PS1ΔE9 mouse [84].”
MethodDobrian, A. D., Ma, Q., Lindsay, J. W., Leone, K. A., Ma, K., Coben, J., Galkina, E. V., & Nadler, J. L. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00463.2010 · Cited by 166 · cited 3×
“Sitagliptin (4 g/kg) also showed similar effects and reduced the expression of mRNA for inflammatory cytokine genes and macrophage infiltration in adipose tissue of high fat diet- (HFD-) induced obese mice [19].”
BackgroundInfluentialLong-term inhibition of dipeptidyl peptidase-4 in Alzheimer’s prone mice
D’Amico, M., Filippo, C. D., Marfella, R., Abbatecola, A. M., Ferraraccio, F., Rossi, F., & Paolisso, G. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.12.004 · Cited by 164 · cited 2×
“In addition, sitagliptin (10 and 20mg/kg) also showed similar anti-inflammatory effects in APPSWE/PS1ΔE9 mouse [93].”
BackgroundActivation of Spinal Glucagon-Like Peptide-1 Receptors Specifically Suppresses Pain Hypersensitivity
Gong, N., Xiao, Q., Zhu, B., Zhang, C.-Y., Wang, Y., Fan, H. J., Ma, A., & Wang, Y. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.4703-13.2014 · Cited by 161
Lee, J., Hong, S.-W., Chae, S. W., Kim, D. H., Choi, J. H., Bae, J. C., Park, S. E., Rhee, E.-J., Park, C.-Y., Oh, K.-W., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031394 · Cited by 157
Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells
Schlatter, P., Beglinger, C., Drewe, J., & Gutmann, H. (2007) · Regulatory Peptides · doi:10.1016/j.regpep.2006.12.016 · Cited by 149 · cited 1×
“The GLP-1 receptor is expressed in glomerular capillaries and vascular walls of themouse kidney [14, 101] and in the glomerulus and proximal convoluted tubules of the rat and pig [29, 102].”
BackgroundAnti-Inflammatory Properties of Sirtuin 6 in Human Umbilical Vein Endothelial Cells
Lappas, M. (2012) · Mediators of Inflammation · doi:10.1155/2012/597514 · Cited by 146
Tremblay, A. J., Lamarche, B., Deacon, C. F., Weisnagel, S. J., & Couture, P. (2014) · Metabolism · doi:10.1016/j.metabol.2014.06.004 · Cited by 132
Hölscher, C. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.12.009 · Cited by 130
Perry, T., & Greig, N. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367892 · Cited by 127 · cited 1×
“GLP-1 is known to be produced in the brain [79] and has many functions including neuroprotection [80–82].”
BackgroundSitagliptin Prevents Inflammation and Apoptotic Cell Death in the Kidney of Type 2 Diabetic Animals
Marques, C., Mega, C., Gonçalves, A., Rodrigues-Santos, P., Teixeira-Lemos, E., Teixeira, F., Fontes-Ribeiro, C., Reis, F., & Fernandes, R. (2014) · Mediators of Inflammation · doi:10.1155/2014/538737 · Cited by 126 · cited 1×
“Sitagliptin (10mg/kg/day) treatment decreased the expression of proinflammatory cytokine genes IL-1β and TNF-α in kidney of diabetic ZDF rat [25].”
BackgroundWang, Y., Parlevliet, E. T., Geerling, J. J., van der Tuin, S. J. L., Zhang, H., Bieghs, V, Jawad, A. H. M., Shiri‐Sverdlov, R., Bot, I., de Jager, S. C. A., et al. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12490 · Cited by 126 · cited 1×
“Exendin-4 treatment reduced hepatic expression of the inflammatory markers TNF-α, IL-1β, and IL-6 and macrophage markers, cluster of differentiation 68 (CD68), and F4/80 in the liver of mice fed a western-type diet [63].”
BackgroundGlucagon‐like peptide 1 receptor stimulation as a means of neuroprotection
Harkavyi, A., & Whitton, P. S. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00486.x · Cited by 125 · cited 1×
“GLP-1 is known to be produced in the brain [79] and has many functions including neuroprotection [80–82].”
BackgroundZeng, Y., Li, C., Guan, M., Zheng, Z., Li, J., Xu, W.-W., Wang, L., He, F., & Xue, Y. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-32 · Cited by 122 · cited 2×
“ited MAPK and ERK1/2 signaling in aorta of ApoE mice [66].”
BackgroundTian, L., Gao, J., Hao, J., Zhang, Y., Yi, H., O'Brien, T. D., Sorenson, R., Luo, J., & Guo, Z. (2010) · Endocrinology · doi:10.1210/en.2010-0068 · Cited by 120
Parthsarathy, V., & Hölscher, C. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.012 · Cited by 119
Dai, Y., Dai, D., Wang, X., Ding, Z., & Mehta, J. L. (2014) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-014-6539-4 · Cited by 116 · cited 3×
“Sitagliptin (25 𝜇M), NVP-DPP728 (270 𝜇M), or liraglutide (1000 ng/mL) treatment significantly reduced oxidizedlow-density lipoprotein-induced or PKC activator-induced protein expression of nucleotide-binding domain-like receptor with a pyrin domain 3 (NLRP3), toll-like receptor 4 (TLR4), and IL-1𝛽 in a human monocytic…”
BackgroundOf Microbes and Meals: The Health Consequences of Dietary Endotoxemia
Kelly, C. J., Colgan, S. P., & Frank, D. N. (2012) · Nutrition in Clinical Practice · doi:10.1177/0884533611434934 · Cited by 116 · cited 1×
“, lipopolysaccharide (LPS)) [56, 57].”
Steven, S., Hausding, M., Kröller-Schön, S., Mader, M., Mikhed, Y., Stamm, P., Zinßius, E., Pfeffer, A., Welschof, P., Agdauletova, S., et al. (2015) · Basic Research in Cardiology · doi:10.1007/s00395-015-0465-x · Cited by 114
Functional pancreatic beta-cell mass: Involvement in type 2 diabetes and therapeutic intervention
Karaca, M., Magnan, C., & Kargar, C. (2009) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.09.007 · Cited by 114 · cited 1×
“GLP-1 has many beneficial effects on the control of blood glucose levels including stimulation of insulin secretion and inhibition of glucagon secretion, expansion of the beta-cell mass by stimulating beta-cell proliferation and differentiation and inhibiting beta-cell apoptosis, delay of gastric emptying, and reducti…”
BackgroundSIRT1 Mediates the Effect of GLP-1 Receptor Agonist Exenatide on Ameliorating Hepatic Steatosis
Xu, F., Li, Z., Zheng, X., Liu, H., Liang, H., Xu, H., Chen, Z., Zeng, K., & Weng, J. (2014) · Diabetes · doi:10.2337/db14-0263 · Cited by 114 · cited 2×
“Liraglutide or exendin-4 (1 nmol/kg/day) treatment dose-dependently reduced steatosis and lobular inflammation in HFD-fed rats or mice compared with the saline-injected group [28, 95], probably due to an increase of SIRT1 [96].”
BackgroundChen, Y.-T., Tsai, T., Yang, C.-C., Sun, C., Chang, L., Chen, H.-H., Chang, C.-L., Sung, P., Zhen, Y., Leu, S., et al. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-270 · Cited by 112 · cited 1×
“In addition, after ischemia-reperfusion injury, the expression of proinflammatory cytokines, NF-κB and ICAM-1, as well as macrophage infiltration in the kidney was significantly decreased by exendin-4 (10 μg/kg) or sitagliptin (600mg/kg) treatment [109].”
BackgroundGLP-1, the Gut-Brain, and Brain-Periphery Axes
Cabou, C., & Burcelin, R. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.418 · Cited by 110
Wang, X.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i40.14821 · Cited by 109
GLP-1 secretion by microglial cells and decreased CNS expression in obesity
Kappe, C., Tracy, L. M., Patrone, C., Iverfeldt, K., & Sjöholm, Å. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-276 · Cited by 107 · cited 1×
“GLP-1 is known to be produced in the brain [79] and has many functions including neuroprotection [80–82].”
BackgroundZhu, T., Wu, X.-L., Zhang, W., & Xiao, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920195 · Cited by 106
Holscher, C. (2010) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488910791213130 · Cited by 102 · cited 1×
“GLP-1 is known to be produced in the brain [79] and has many functions including neuroprotection [80–82].”
BackgroundKodera, R., Shikata, K., Takatsuka, T., Oda, K., Miyamoto, S., Kajitani, N., Hirota, D., Ono, T., Usui, H. K., & Makino, H. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.12.049 · Cited by 101
Vittone, F., Liberman, A., Vasic, D., Ostertag, R., Esser, M., Walcher, D., Ludwig, A., Marx, N., & Burgmaier, M. (2012) · Diabetologia · doi:10.1007/s00125-012-2582-5 · Cited by 97 · cited 3×
“Another report showed that sitagliptin (576mg/kg) reduced plaque macrophage infiltration and matrix metallopeptidase-9 (MMP-9) levels in ApoE mice [26] and increased activation of AMPK and AKT signaling pathway but inhibited MAPK and ERK1/2 signaling in aorta of ApoE mice [66].”
BackgroundInfluentialSolmaz, V., Çınar, B. P., Yiğittürk, G., Çavuşoğlu, T., Taşkıran, D., & Erbaş, O. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.09.024 · Cited by 96
The Role of Anti-Inflammatory Agents in Parkinson???s Disease
McGeer, E. G., & McGeer, P. L. (2007) · CNS Drugs · doi:10.2165/00023210-200721100-00001 · Cited by 95 · cited 1×
“Neurodegenerative central nervous system disorders are associated with chronic neuroinflammation [75–77].”
BackgroundNakashima, S., Matsui, T., Takeuchi, M., & Yamagishi, S.-I. (2014) · Hormone and Metabolic Research · doi:10.1055/s-0034-1371892 · Cited by 90 · cited 1×
“Administration of the DPP-4 inhibitor, PKF275-055 (3mg/kg/day), or linagliptin in STZ-induced diabetic rats inhibited macrophage infiltration, inflammatorymolecules, andNF-κB activity in the glomeruli [105] and significantly reduced glomerular leukocyte infiltration [106].”
BackgroundBurgmaier, M., Liberman, A., Möllmann, J., Kahles, F., Reith, S., Lebherz, C., Marx, N., & Lehrke, M. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.08.033 · Cited by 82
Blandino-Rosano, M., Perez-Arana, G., Mellado-Gil, J. M., Segundo, C., & Aguilar-Diosdado, M. (2008) · Journal of Molecular Endocrinology · doi:10.1677/jme-07-0154 · Cited by 82
Katagiri, D., Hamasaki, Y., Doi, K., Okamoto, K., Negishi, K., Nangaku, M., & Noiri, E. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013020134 · Cited by 81
Anti-inflammatory role of DPP-4 inhibitors in a nondiabetic model of glomerular injury
Higashijima, Y., Tanaka, T., Yamaguchi, J., Tanaka, S., & Nangaku, M. (2015) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00590.2014 · Cited by 75
Zhang, E., Xu, F., Liang, H., Yan, J., Xu, H., Li, Z., Wen, X., & Weng, J. (2015) · American Journal of Reproductive Immunology · doi:10.1111/aji.12420 · Cited by 73 · cited 2×
“The expression of TNF-α, MCP-1, and F4/80mRNA levels is increased in the testis and significantly decreased the sperm motility and activity in diet-induced obesity mice, and exenatide (24 nmol/kg/day) treatment suppressed the expression of TNF-α,MCP-1, andF4/80mRNA levels in testis and improved sperm quality in diet-i…”
BackgroundSancar-Bas, S., Gezginci-Oktayoglu, S., & Bolkent, S. (2015) · Growth Factors · doi:10.3109/08977194.2015.1125349 · Cited by 71 · cited 1×
“Exendin-4 (3 and 10 μg/kg/day) treatment significantly downregulated the gene expression of CD14, ICAM-1, and TGFβ1 in the renal cortex, prevented glomerular macrophage infiltration in glomeruli, and reduced oxidative stress and inflammation in tubular cells in STZ-induced diabetic animals [101, 103].”
BackgroundDerosa, G., Franzetti, I. G., Querci, F., Carbone, A., Ciccarelli, L., Piccinni, M. N., Fogari, E., & Maffioli, P. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03699.x · Cited by 70
Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes
Gangadharan Komala, M., Gross, S., Zaky, A., Pollock, C., & Panchapakesan, U. (2016) · Nephrology · doi:10.1111/nep.12618 · Cited by 68 · cited 1×
“Treatment with the DPP-4 inhibitor, saxagliptin (10mg/kg/day), reduced renal tubulointerstitial inflammation by NF-κBp65-mediated macrophage infiltration in STZinduced diabetic enos mice [104].”
BackgroundAnti-Inflammatory Properties of Exenatide in Human Pancreatic Islets
Cechin, S. R., Pérez-Álvarez, I., Fenjves, E., Molano, R. D., Pileggi, A., Berggren, P.-O., Ricordi, C., & Pastori, R. L. (2012) · Cell Transplantation · doi:10.3727/096368911x576027 · Cited by 67
GOU, S., ZHU, T., WANG, W., XIAO, M., WANG, X.-C., & CHEN, Z.-H. (2014) · International Immunopharmacology · doi:10.1016/j.intimp.2014.07.010 · Cited by 66
Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology
Drucker, D. J., & Rosen, C. F. (2011) · Diabetologia · doi:10.1007/s00125-011-2297-z · Cited by 66 · cited 1×
“In type 2 diabetes patients, GLP-1 and liraglutide also improve clinical symptoms of psoriasis, a skin inflammatory disease, by downregulation of invariant natural killer T cells [31, 113, 114].”
BackgroundFaurschou, A., Knop, F. K., Thyssen, J. P., Zachariae, C., Skov, L., & Vilsbøll, T. (2014) · Acta Diabetologica · doi:10.1007/s00592-011-0359-9 · Cited by 65 · cited 1×
“In type 2 diabetes patients, GLP-1 and liraglutide also improve clinical symptoms of psoriasis, a skin inflammatory disease, by downregulation of invariant natural killer T cells [31, 113, 114].”
BackgroundPugazhenthi, U., Velmurugan, K., Tran, A., Mahaffey, G., & Pugazhenthi, S. (2010) · Diabetologia · doi:10.1007/s00125-010-1849-y · Cited by 61
Glucagon-like peptide-1 protects mesenteric endothelium from injury during inflammation
Dozier, K. C., Cureton, E. L., Kwan, R. O., Curran, B., Sadjadi, J., & Victorino, G. P. (2009) · Peptides · doi:10.1016/j.peptides.2009.06.019 · Cited by 58 · cited 1×
“0 μM) perfusion attenuates LPS-inducedmicrovascular permeability via the cAMP protein kinase A (PKA) pathway [59].”
BackgroundSalim, H. M., Fukuda, D., Higashikuni, Y., Tanaka, K., Hirata, Y., Yagi, S., Soeki, T., Shimabukuro, M., & Sata, M. (2016) · Vascular Pharmacology · doi:10.1016/j.vph.2015.08.011 · Cited by 56 · cited 1×
“inhibitor, to ApoE mice, an animal model of atherosclerosis, decreased inflammatory molecule expression and macrophage infiltration in the atherosclerotic aorta [65].”
BackgroundAo, N., Yang, J., Wang, X., & Du, J. (2016) · Hepatology Research · doi:10.1111/hepr.12551 · Cited by 56
Glucagon‐like peptide‐1 protects synaptic and learning functions from neuroinflammation in rodents
Iwai, T., Sawabe, T., Tanimitsu, K., Suzuki, M., Sasaki‐Hamada, S., & Oka, J. (2014) · Journal of Neuroscience Research · doi:10.1002/jnr.23335 · Cited by 55 · cited 2×
“Lixisenatide Neurodegenerative brain disorder [90]”
BackgroundAntiapoptotic Actions of Exendin-4 against Hypoxia and Cytokines Are Augmented by CREB
Velmurugan, K., Balamurugan, A. N., Loganathan, G., Ahmad, A., Hering, B. J., & Pugazhenthi, S. (2012) · Endocrinology · doi:10.1210/en.2011-1895 · Cited by 53 · cited 1×
“As well, exendin-4 (50 nM) and cyclic adenosine monophosphate (cAMP) response elementbinding protein overexpression additively protected transplanted human islets in streptozotocin- (STZ-) induced diabetic nude mice [44].”
BackgroundRomaní-Pérez, M., Outeiriño-Iglesias, V., Gil-Lozano, M., González-Matías, L. C., Mallo, F., & Vigo, E. (2013) · Endocrinology · doi:10.1210/en.2012-1786 · Cited by 51 · cited 1×
“Expression of the GLP-1 receptor is widely detected in various cells and organs including the kidney, lung, heart, hypothalamus, endothelial cells, neurons, astrocytes, and microglia as well as pancreatic beta-cells [12–17], suggesting that GLP-1 might have additional roles other than glucoselowering effects.”
BackgroundClinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors
Varanasi, A., Patel, P., Makdissi, A., Dhindsa, S., Chaudhuri, A., & Dandona, P. (2012) · Endocrine Practice · doi:10.4158/ep11169.or · Cited by 50
Jensen, T. M., Saha, K., & Steinberg, W. M. (2015) · Diabetes Care · doi:10.2337/dc13-1210 · Cited by 48 · cited 1×
“However, some rare cases of acute pancreatitis and neoplasms have been reported [53–55]; thus the establishment of safety of GLP-1-based therapy should be validated by sufficient further studies.”
BackgroundPark, C., Kim, J.-R., Shim, J.-K., Kang, B.-S., Park, Y.-G., Nam, K.-S., Lee, Y.-C., & Kim, C.-H. (1999) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1998.1004 · Cited by 47
Self-citationTang, S.-T., Zhang, Q., Tang, H.-Q., Wang, C.-J., Su, H., Zhou, Q., Wei, W., Zhu, H.-Q., & Wang, Y. (2016) · Endocrine · doi:10.1007/s12020-015-0852-y · Cited by 46
Akita, K., Isoda, K., Shimada, K., & Daida, H. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001469 · Cited by 43
Endogenous GLP-1 as a key self-defense molecule against lipotoxicity in pancreatic islets
HUANG, C., YUAN, L., & CAO, S. (2015) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2207 · Cited by 41 · cited 3×
“Young-Sun Lee1 and Hee-Sook Jun1,2,3 1Lee Gil Ya Cancer and Diabetes Institute, Gachon University, 7-45 Songdo-dong, Yeonsu-ku, Incheon 406-840, Republic of Korea 2College of Pharmacy and Gachon Institute of Pharmaceutical Science, Gachon University, 7-45 Songdo-dong, Yeonsu-ku, Incheon 406-840, Republic of Korea 3Gac…”
BackgroundDorecka, M., Siemianowicz, K., Francuz, T., Garczorz, W., Chyra, A., Klych, A., & Romaniuk, W. (2013) · Pharmacological Reports · doi:10.1016/s1734-1140(13)71069-7 · Cited by 36 · cited 1×
“GLP-1 (100 nM) or exendin-4 (10 nM) treatment inhibited TNF-α-induced expression of receptor for advanced glycation end products (RAGE), ICAM-1, and VCAM-1 in human retinal pigment epithelial cells [32], suggesting that GLP1-based therapies might have beneficial effects on diabetic retinopathy.”
BackgroundLiu, Y., Huang, Z., Wang, L., Liu, X., Wang, Y.-M., Zhang, Y., & Zhang, M. (2014) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2014.12.007 · Cited by 35 · cited 1×
“Sitagliptin (30 and 50mg/kg/day) reduced the expression of TNF-α and IL-6 in the diabetic heart and had amyocardial protective effect in STZ/HFD-induced diabetic rats [74].”
BackgroundPancreatitis: A Potential Complication of Liraglutide?
Franks, A. S., Lee, P. H., & George, C. M. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q789 · Cited by 34
Cai, Y., Hu, X., Yi, B., Zhang, T., & Wen, Z. (2012) · Molecular Biology Reports · doi:10.1007/s11033-012-1961-9 · Cited by 31
Akarte, A. S., Srinivasan, B. P., Gandhi, S., & Sole, S. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.07.003 · Cited by 28 · cited 3×
“Young-Sun Lee1 and Hee-Sook Jun1,2,3 1Lee Gil Ya Cancer and Diabetes Institute, Gachon University, 7-45 Songdo-dong, Yeonsu-ku, Incheon 406-840, Republic of Korea 2College of Pharmacy and Gachon Institute of Pharmaceutical Science, Gachon University, 7-45 Songdo-dong, Yeonsu-ku, Incheon 406-840, Republic of Korea 3Gac…”
BackgroundAnti-inflammatory effect of exendin-4 postconditioning during myocardial ischemia and reperfusion
Du, X., Hu, X., & Wei, J. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3252-0 · Cited by 21
Zhang, Y., Chen, Y., Cheng, J., Guo, Z., Lu, Y., & Tian, B. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.11.048 · Cited by 13 · cited 3×
“Young-Sun Lee1 and Hee-Sook Jun1,2,3 1Lee Gil Ya Cancer and Diabetes Institute, Gachon University, 7-45 Songdo-dong, Yeonsu-ku, Incheon 406-840, Republic of Korea 2College of Pharmacy and Gachon Institute of Pharmaceutical Science, Gachon University, 7-45 Songdo-dong, Yeonsu-ku, Incheon 406-840, Republic of Korea 3Gac…”
Background
Cited by
COVID-19 and diabetes mellitus: from pathophysiology to clinical management
Lim, S., Bae, J. H., Kwon, H.-S., & Nauck, M. A. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00435-4 · Cited by 1,006
Trends in insulin resistance: insights into mechanisms and therapeutic strategy
Li, M., Chi, X., Wang, Y., Setrerrahmane, S., Xie, W., & Xu, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01073-0 · Cited by 939
“These GLP-1 receptor agonists can suppress the inflammatory response of macrophages, thereby inhibiting IR.(469) (2) Dipeptidyl peptidase-4 (DPP-4) also referred as the T-cell antigen CD26 can degrade GLP-1.”
BackgroundResearch Progress on the Relationship between Atherosclerosis and Inflammation
Zhu, Y., Xian, X., Wang, Z., Bi, Y., Chen, Q., Han, X., Tang, D., & Chen, R. (2018) · Biomolecules · doi:10.3390/biom8030080 · Cited by 872
“Therefore, PLA2 inhibitors need to be studied in clinical trials [73].”
BackgroundVascular Inflammation and Oxidative Stress: Major Triggers for Cardiovascular Disease
Steven, S., Frenis, K., Oelze, M., Kalinovic, S., Kuntic, M., Bayo Jimenez, M. T., Vujacic-Mirski, K., Helmstädter, J., Kröller-Schön, S., Münzel, T., et al. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/7092151 · Cited by 708
The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists
Bendotti, G., Montefusco, L., Lunati, M. E., Usuelli, V., Pastore, I., Lazzaroni, E., Assi, E., Seelam, A. J., El Essawy, B., Jang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106320 · Cited by 406
Metadata
- Authors
- Lee, Y.-S., & Jun, H.-S.
- Affiliations
- Gachon University (KR)
- Corresponding author
- Jun, Hee-Sook
- Venue
- Mediators of Inflammation
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-11
- ISSN
- 0962-9351 (ISSN-L)
- 1466-1861
- PMC
- PMC4823510
- OpenAlex
- W2306319461
- Cited by
- 530
- References
- 116
- Citations by year
- 2026: 68 · 2025: 83 · 2024: 56 · 2023: 52 · 2022: 60 · 2021: 72 · 2020: 53 · 2019: 47 · 2018: 21 · 2017: 15 · 2016: 3
- FWCI
- 3.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Mediators of Inflammation (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Research Foundation of Korea (2015R1D1A1A01060232)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Keywords
- glucagon-like peptide-1, GLP-1 receptor agonists, DPP-4 inhibitors, anti-inflammatory activity, chronic inflammation, type 2 diabetes, type 1 diabetes, atherosclerosis, neurodegenerative diseases, nonalcoholic steatohepatitis, diabetic nephropathy, asthma, psoriasis, glucose homeostasis, molecular mechanisms of inflammation
- MeSH terms
- Animals, Anti-Inflammatory Agents, Blood Glucose, Diabetes Mellitus, Type 2, Humans, Inflammation, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.